IN2014DN03325A - - Google Patents

Info

Publication number
IN2014DN03325A
IN2014DN03325A IN3325DEN2014A IN2014DN03325A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A IN 3325DEN2014 A IN3325DEN2014 A IN 3325DEN2014A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A
Authority
IN
India
Prior art keywords
compound
directed
composition
sulphur
selene
Prior art date
Application number
Other languages
English (en)
Inventor
Ferdinand Antonius Ossendorp
Cornelis Johannes Maria Melief
Selina Khan
Dmitri Viktorovitsj Filippov
Marel Gijsbert Arie Van Der
Original Assignee
Isa Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V filed Critical Isa Pharmaceuticals B V
Publication of IN2014DN03325A publication Critical patent/IN2014DN03325A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IN3325DEN2014 2011-10-05 2012-10-04 IN2014DN03325A (enrdf_load_html_response)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (1)

Publication Number Publication Date
IN2014DN03325A true IN2014DN03325A (enrdf_load_html_response) 2015-06-26

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3325DEN2014 IN2014DN03325A (enrdf_load_html_response) 2011-10-05 2012-10-04

Country Status (16)

Country Link
US (2) US9314521B2 (enrdf_load_html_response)
EP (1) EP2763697B9 (enrdf_load_html_response)
JP (1) JP6099210B2 (enrdf_load_html_response)
KR (1) KR102053699B1 (enrdf_load_html_response)
CN (1) CN104244976B (enrdf_load_html_response)
AU (1) AU2012319265B2 (enrdf_load_html_response)
BR (1) BR112014008214B1 (enrdf_load_html_response)
CA (1) CA2886631C (enrdf_load_html_response)
EA (1) EA030741B1 (enrdf_load_html_response)
ES (1) ES2952644T3 (enrdf_load_html_response)
IL (1) IL231951B (enrdf_load_html_response)
IN (1) IN2014DN03325A (enrdf_load_html_response)
MX (1) MX356028B (enrdf_load_html_response)
NL (1) NL2007536C2 (enrdf_load_html_response)
SG (1) SG11201401291XA (enrdf_load_html_response)
WO (1) WO2013051936A1 (enrdf_load_html_response)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2976325T3 (en) 2013-03-21 2017-06-06 Sanofi Aventis Deutschland SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
EP2976331B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of hydantoin containing peptide products
US10576144B2 (en) 2013-06-28 2020-03-03 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
JP6780852B2 (ja) 2014-06-02 2020-11-04 アイエスエー ファーマシューティカルズ ビー.ヴイ.ISA Pharmaceuticals B.V. B型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド(slp)
EP3237374A4 (en) 2014-12-23 2018-04-25 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
PE20230343A1 (es) 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
EA201891639A1 (ru) 2016-02-26 2019-06-28 Окленд Юнисервисес Лимитед Аминокислотные и пептидные конъюгаты и способ конъюгации
KR20230030032A (ko) 2016-06-20 2023-03-03 아이에스에이 파마슈티컬즈 비.브이. 펩타이드 백신의 제형
ES2990113T3 (es) 2016-07-07 2024-11-28 The Board Of Trustees Of The Leland Stanfordjunior Univ Conjugados de adyuvantes de anticuerpos
IL302880A (en) 2017-04-04 2023-07-01 Avidea Tech Inc Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
CN113993549A (zh) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 靶向her2的免疫缀合物
BR112022011099A2 (pt) 2019-12-07 2022-08-23 Isa Pharmaceuticals B V Tratamento de doenças relacionadas ao vírus da hepatite b
US20230087422A1 (en) 2020-02-07 2023-03-23 Isa Pharmaceuticals B.V. Treatment of hpv-related diseases
EP4138876A1 (en) 2020-04-23 2023-03-01 ISA Pharmaceuticals B.V. Immunization against sars-cov-related diseases
EP4370903A1 (en) 2021-07-12 2024-05-22 ISA Pharmaceuticals B.V. Improved substance quantification in complex mixtures
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
WO2024079311A1 (en) 2022-10-13 2024-04-18 Isa Pharmaceuticals B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NZ516381A (en) 1999-06-30 2004-03-26 Corixa Corp Lung tumor proteins in the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
NZ526326A (en) 2000-12-08 2006-09-29 Academisch Ziekenhuis Leiden A CTL epitope petide of 22-45 amino acid residues for inducing and/or enhancing an antigen-specific T-cell response
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
EP2462947B1 (en) 2007-03-26 2019-03-13 Academisch Ziekenhuis Leiden h.o.d.n. LUMC PRAME derived peptides and immunogenic compositions comprising these
EP3584251A3 (en) 2007-05-31 2020-01-29 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
ES2406077T3 (es) 2007-05-31 2013-06-05 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vacuna de péptido p53
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
CN102905703B (zh) * 2010-03-23 2016-09-28 诺华股份有限公司 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物

Also Published As

Publication number Publication date
CA2886631C (en) 2019-06-11
EP2763697C0 (en) 2023-06-07
EP2763697B8 (en) 2023-07-12
JP6099210B2 (ja) 2017-03-22
US9314521B2 (en) 2016-04-19
KR20140093673A (ko) 2014-07-28
US20160250325A1 (en) 2016-09-01
EA201490709A1 (ru) 2014-09-30
IL231951A0 (en) 2014-05-28
MX356028B (es) 2018-05-09
US20150104473A1 (en) 2015-04-16
EP2763697B1 (en) 2023-06-07
WO2013051936A9 (en) 2013-09-12
SG11201401291XA (en) 2014-05-29
EA030741B1 (ru) 2018-09-28
EP2763697A1 (en) 2014-08-13
AU2012319265B2 (en) 2016-10-13
MX2014004114A (es) 2014-10-17
CN104244976A (zh) 2014-12-24
BR112014008214A2 (pt) 2017-06-13
JP2014530808A (ja) 2014-11-20
ES2952644T3 (es) 2023-11-02
WO2013051936A1 (en) 2013-04-11
NL2007536C2 (en) 2013-04-08
AU2012319265A1 (en) 2014-05-22
CN104244976B (zh) 2017-05-31
IL231951B (en) 2019-08-29
US9770506B2 (en) 2017-09-26
BR112014008214B1 (pt) 2022-07-05
NZ623869A (en) 2015-11-27
EP2763697B9 (en) 2023-10-04
KR102053699B1 (ko) 2019-12-09
CA2886631A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
IN2014DN03325A (enrdf_load_html_response)
WO2016077464A8 (en) Amino acid derivatives and their uses
MY200083A (en) Cyclic dinucleotide compounds
BR112012007411A2 (pt) composto, processo para sua preparação e composição farmacêutica contendo o mesmo
TR201900128T4 (tr) Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller.
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
MY159252A (en) Process for the preparation of dopo-derived compounds and compositions thereof
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
BR112013020996A2 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
MY150596A (en) Hsp90 inhibitors
PH12012502352A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
JO2910B1 (en) Organic compounds
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
MX2011007952A (es) Tricianoboratos novedosos.
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
MX352607B (es) Proceso para la preparacion de benzoxaboroles.
BR112013001132A2 (pt) processo para preparação de compostos antivirais
MY167638A (en) Treatment composition for textile goods
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
NZ704155A (en) Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof
MX2013003387A (es) Proceso para preparacion de producto de reaccion de urea ciclica y de aldehido multifuncional.
UY32975A (es) Derivados de aminopiridina
BR112013024361A2 (pt) novos compostos de azaspirodecanona como inibidores de hsl
EA201390170A1 (ru) Составы
BR112012029944A2 (pt) processo para preparação de derivados de aminotetralinas substituídas com nitrogênio